Treatment outcomes of the LBBAP
Six studies assessed the effects of LBBAP on NT-pro BNP levels between pre- and post-procedural treatment. LBBAP significantly lowered NT-pro BNP levels, with mean difference of −674.89 pg/ml (95% CI −1103.72 to −246.06, I2 = 93.8%). Furthermore, 13 studies assessed the effects of LBBAP on NYHA classification between pre- and post-procedural treatment, over 6–12 months of follow-up. LBBAP was also associated with a significant improvement of NYHA classification, with a mean difference of −1.25 (95% CI −1.46 to −1.04, I2 = 87.9%), with no differences between the Chinese and non-Chinese population (−1.27 vs. −1.24, p= 0.90) and the PICM and non-PICM patients (−1.02 vs. −1.31, p = 0.28).